Chronic Hepatitis B Prevalence Among Foreign-Born Persons Living in the United States

Telemedicine Consult - Dr. Gish

Schedule Telemedicine Consult with Dr. Gish

For appointments

Call the office

Folsom, California Office: 916-983-4444

Call Now

Close

WHO:

Dr. Gish is a Hepatologist specializing in all forms of liver disease, liver cancer and liver transplant. Dr. Gish has partnered with TeleMed2U to provide telemedicine consultative services for patients with liver disease.

WHAT:

TeleMed2U is a telemedicine-based multi-specialty clinical practice increasing access to specialist providers providing, “healthcare anywhere and everywhere.” The telemedicine consultation will be conducted through our HIPAA and HITECH compliant platform. Connectivity testing will be done in advance to ensure you can connect via our telemedicine platform. Following the consultation, a clinical note will be provided including a summary of your liver consultation with Dr. Gish and his consultative recommendations.

COST:

Payment will be processed through an online secure transaction portal. The fees for consultative services are:

Initial 60 minute consultation per patient: $500.00
Follow Up 30 minute consultation per patient: $300.00

NEXT STEPS:

If you’d like to continue, please click Next to complete the form and we will contact you to schedule connectivity testing. During the test you will have the opportunity to determine the method of providing medical records, discuss appointment availability as well as discuss any additional questions that you have. If you are a healthcare facility interested in services, please complete the form and we can discuss the options that are right for you and your patients.

Email

Subject

Country

You should be aware of the general risks of transmitting information over the Internet, which may not use encryption. You should therefore not share any personal medical information that you would wish to be held confidential in a physician/patient or similar clinical relationship.

The information contained on this website is not intended, should not substitute for, or be used instead of, a clinical or therapeutic relationship with a health care professional who is fully familiar with the specifics of your case. The information on this site may assist you in your personal, general research but none of it constitutes the practice of medicine or any other health care profession.

Nothing in this site is intended as a recommendation or endorsement of any specific tests, products, procedures, healthcare provider, opinions, or other information that may be mentioned in this site. Any reliance on any information provided by the website personnel, others appearing on the site at the invitation of the website and/or other visitors to the site is solely at the user's risk.

E-mail correspondence with Dr. Robert G. Gish Consultants, LLC or any of its employees, or agents, does not create a physician/patient relationship between us or cause Dr. Gish to create or retain any medical records about you, monitor your care, or communicate with your own health care provider.

Always seek the advice of your physician or other qualified health care provider with any questions you have regarding your medical care. If you suspect that you may have a medical condition, or are seeking medical advice or treatment, we recommend that you consult a qualified health professional as soon as possible.

Powered by

Close Form

Chronic Hepatitis B Prevalence Among Foreign-Born Persons Living in the United States

May 12, 2021

An Updated Assessment of Chronic Hepatitis B Prevalence Among Foreign-Born Persons Living in the United States

While prevalence of chronic hepatitis B (CHB) in the United States (U.S.) includes 0.42 million (range 0.28-0.67) U.S.-born individuals, foreign-born (FB) persons contribute a substantially larger number to the burden of CHB in the United States. Over the past decade, patterns of U.S. immigration have changed and many countries have implemented hepatitis B virus prevention programs. This study aims to estimate the number of FB persons with CHB in the U.S. by country of origin, updating our 2011 study. We performed systematic searches for articles published in 2009-2019 reporting hepatitis B surface antigen seroprevalence in emigrants and in-country populations of 117 countries. Data meeting inclusion criteria were combined with data from our 2011 study to calculate pooled prevalence estimates for 99 countries using meta-analyses (total 2,800 surveys involving 112 million subjects). Combining country-specific CHB rate estimates with the number of FB in the U.S. in 2018, by country of origin from the U.S. Census Bureau, we estimate the number of FB with CHB in the U.S. in 2018 was 1.47 million (95% confidence interval: 1.21-1.73), substantially higher than previously reported. The weighted average CHB prevalence for all FB in the U.S. in 2018 was 3.07%. About 59% of FB with CHB in the U.S. in 2018 emigrated from Asia, 19% from the Americas, and 15% from Africa. Subgroup analyses found that for many countries, CHB rates are higher in males than females and have declined over the past three decades, but no consistent pattern is seen between emigrant and in-country rates. Conclusion: Including FB and U.S.-born persons, the total prevalence of CHB in the U.S. may be as high as 2.4 million.

Read Full Article

Metadata